Cargando…

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model

BACKGROUND: Despite the numerous applications of monoclonal antibodies (mAbs) in cancer therapeutics, animal models available to test the therapeutic efficacy of new mAbs are limited. NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NSG) mice are one of the most highly immunodeficient strains and are universal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Jing, Wang, Lan, Ren, Jie, Kranz, Emiko, Chen, Shilin, Wu, Di, Kanazawa, Toshio, Chen, Irvin, Lu, Yunfeng, Kamata, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888328/ https://www.ncbi.nlm.nih.gov/pubmed/33593826 http://dx.doi.org/10.1136/jitc-2020-001524

Ejemplares similares

Correction: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Publicado: (2021)

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
por: Krieg, Carsten, et al.
Publicado: (2022)

Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates
por: Qin, Meng, et al.
Publicado: (2020)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
por: Mustafa, Nurulhuda, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models
por: Stirm, Kristin, et al.
Publicado: (2023)

Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance
por: Zou, Xuan, et al.
Publicado: (2023)

IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
por: Stifter, Katja, et al.
Publicado: (2020)

Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma
por: Wu, Hongyan, et al.
Publicado: (2021)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma
por: Deng, Yuwei, et al.
Publicado: (2021)

Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses
por: Zhang, Shuai, et al.
Publicado: (2023)

Cellular cytotoxicity is a form of immunogenic cell death
por: Minute, Luna, et al.
Publicado: (2020)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
por: Lopes, Jared E, et al.
Publicado: (2020)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2
por: Jiang, Mengmeng, et al.
Publicado: (2022)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
por: Chen, Saisai, et al.
Publicado: (2023)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression
por: Chen, Chunxia, et al.
Publicado: (2022)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation
por: Qin, Rui, et al.
Publicado: (2021)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
por: Chen, Heyu, et al.
Publicado: (2020)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
por: Chen, Lujun, et al.
Publicado: (2022)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts
por: Woolaver, Rachel A, et al.
Publicado: (2021)

AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
por: Zhang, Ganggang, et al.
Publicado: (2023)

Fetal exposure to oncoantigen elicited antigen-specific adaptive immunity against tumorigenesis
por: Chen, Jeng-Chang, et al.
Publicado: (2020)

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ma0jj7730tn2njp57g0il5k8e